Enterprise Value
3.687B
Cash
1.059B
Avg Qtr Burn
-97.33M
Short % of Float
32.38%
Insider Ownership
15.35%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Rezdiffra (Resmetirom) (MGL-3196) (THR-B Agonist) Details Non-alcoholic steatohepatitis , Liver disease | Approved Quarterly sales | |
Resmetirom (MGL-3196) (THR-B Agonist) Details Fatty liver disease, Liver disease | Phase 3 Data readout |